Clinical Trials | May 21, 2024
Modular ATP study of the mCRM System meets primary safety and efficacy endpoints
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Additional data from APPRAISE ATP trial reinforce modular therapy approach
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
The project funding will be done through a mix of internal accruals and debts.
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Subscribe To Our Newsletter & Stay Updated
